Case series of outcomes with tamilogene laherparepvec in pretreated soft tissue sarcoma

Tamilogene laherparepvec (T-VEC) is an intralesional therapy designed to elicit an immunogenic antitumor response. In a phase 2 trial, T-VEC had a favorable safety profile in sarcoma patients; however, there is a paucity of data on its therapeutic efficacy. Four sarcoma patients of The Ohio State University Medical Center (Columbus, OH), who had prior progression of disease on immune checkpoint inhibitors, received a median of 9.5 (range 4-15) doses of T-VEC over 26.5 (10-49) weeks. The median progression-free survival was 9 weeks (range 9-10). Only one patient experienced toxicity, which presented as mild flu-like symptoms. The authors conclude that intralesional T-VEC may be administered safely and may provide local tumor control in select patients with sarcoma who have failed prior therapy with immune checkpoint inhibitors.